Prescription Drug Pricing
COVID-19 Solutions Fast-Tracked
Gilead relinquished its orphan drug status for remdesivir shortly after receivin...
May 31, 2020
Out of Reach?
New models for financing and providing rare disease treatment could make for a s...
May 31, 2020
Parsing the Drug Supply Chain
Q&A with Eric Levin, CEO of Scripta Insights
April 27, 2020
PBGH Drug Formulary Study
Q&A with Lauren Vela, Senior Director of Member Value, Pacific Business Group on...
March 1, 2020
Hospitals and Insurers Team Up to Manufacture Generic Drugs
Unlikely advocates support lowering prescription drug costs
February 19, 2020
What Prescription Drug Importation Could Mean for Brokers
Q&A with David Shore, SVP, Enterprise Strategy & Risk Management at Borislow Ins...
August 14, 2019
Can insurers and PBMs harness their combined data to truly know the patient bett...
May 24, 2019
Prescription Back-Door Discounts
Q&A with Steve Wojcik, VP, National Business Group on Health; Caleb Alexander, c...
April 19, 2019
Cloudy…with a Chance of Optimism
Blue Dogs to bipartisanship to herbal tea—The Council’s government affairs t...
January 22, 2019
Tech Giants Poised to Shift Healthcare Landscape
Tech companies are banging down the doors of the healthcare industry, infiltrati...
December 5, 2018
Show More in Prescription Drug Pricing